Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Staphylococcus aureus immune globulin intravenous
- Development stage
- Preclinical
- Lead developer
- Vaxart
- Modality
- Recombinant Proteins and Enzymes, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Staphylococcus aureus immune globulin intravenous is a human-derived immunoglobulin preparation enriched with antibodies targeting Staphylococcus aureus antigens. It is designed to provide passive immunity and enhance the host's ability to neutralize S. aureus toxins and virulence factors, such as leukocidins like LukAB[1][2]. The product is typically used in severe or invasive S. aureus infections where additional antibody-mediated immunity may be beneficial[1]. Its mechanism of action involves supplying exogenous polyclonal IgG antibodies that bind to and neutralize bacterial toxins and facilitate opsonization for enhanced phagocytosis[1]. This drug was initially developed by Nabi Biopharmaceuticals and later by Biotest[4].
- Other names
- staphylococcus aureus immune globulin (human)S. aureus IVIG
02
Targets
CP8 (Staphylococcus aureus capsular polysaccharide type 8)CP5 (Staphylococcus aureus capsular polysaccharide type 5)
Beyond the preview
Go deeper on Staphylococcus aureus immune globulin intravenous.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Staphylococcus aureus immune globulin intravenous.